Results 51 to 60 of about 8,552 (153)
Phytotherapy Research, EarlyView.This review summarizes how natural products, mainly including flavonoids, terpenoids, alkaloids, and polyphenols alleviate RA via PI3K/Akt pathway, regulating inflammation, proliferation, apoptosis, angiogenesis, and osteoclast differentiation. The figure was created by Figdraw (https://www.figdraw.com/#/).
Haishuo Ren +10 more
wiley +1 more source
Zhongguo cuzhong zazhi成纤维细胞生长因子23（fibroblast growth factor 23，FGF23）-Klotho内分泌轴参与磷酸盐代谢，研究提示该内分泌轴与卒中的发病机制密切相关。FGF23、Klotho水平均与卒中的发病及预后有关。FGF23-Klotho内分泌轴参与调节血管壁炎症反应，并可能参与高血压、胰岛素抵抗、脂代谢及肥胖等卒中危险因素的病理过程。本文介绍FGF23-Klotho内分泌轴对卒中的影响及可能机制的相关研究进展，以期为临床治疗和预防卒中带来新的思路。 Abstract ...
宋晓1，卢克良1，吴春艳2 (SONG Xiao1, LU Keliang1, WU Chunyan2 )
doaj +1 more source
The production of fibroblast growth factor 23 is controlled by TGF-β2
Scientific Reports, 2017 Transforming growth factor-β (TGF-β) is a cytokine produced by many cell types and implicated in cell growth, differentiation, apoptosis, and inflammation.
Martina Feger +6 more
doaj +1 more source
FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice
JCI Insight, 2023 Fibroblast growth factor 23 (FGF23) is a phosphate-regulating (Pi-regulating) hormone produced by bone. Hereditary hypophosphatemic disorders are associated with FGF23 excess, impaired skeletal growth, and osteomalacia. Blocking FGF23 became an effective
Guillaume Courbon +15 more
doaj +1 more source
Complications and Treatments in Adult X-Linked Hypophosphatemia
Endocrines, 2022 X-linked hypophosphatemia (XLH) is a rare inherited disorder involving elevated levels of fibroblast growth factor (FGF) 23, and is caused by loss-of-function mutations in the PHEX gene. FGF23 induces renal phosphate wasting and suppresses the activation
Yasuo Imanishi +2 more
doaj +1 more source
Hypophosphataemia in adults: approach to diagnosis and management
Internal Medicine Journal, EarlyView.Abstract Hypophosphataemia is a common electrolyte disorder which can have clinically significant consequences for bone, muscle, neurological and haematological function. Its causes range from transient transcellular shifts in hospitalised patients to chronic renal phosphate‐wasting disorders mediated by fibroblast growth factor 23 (FGF23).
Kajanan Parameshwaran +2 more
wiley +1 more source
Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
Bone ReportsCutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare bone disorder featuring fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic rickets.
Lillian Abebe +13 more
doaj +1 more source
Journal of Animal Physiology and Animal Nutrition, EarlyView.ABSTRACT The transition from immature pullets to sexually mature female chickens is accompanied by pronounced structural and functional modifications. This is accompanied by coordinated changes in hormonal and metabolic pathways that primarily regulate reproduction, nutrient utilization, and mineral homeostasis to compensate for temporary imbalances ...
Henry Reyer +6 more
wiley +1 more source
Impact of systemic diseases on periodontal remodeling: Mechanisms, mediators, and clinical relevance
Periodontology 2000, EarlyView.Abstract Background Periodontal remodeling is a continuous, adaptive process essential for maintaining the structural and functional integrity of periodontal tissues. While external factors such as bacterial biofilm, excessive forces, and poor oral hygiene are recognized triggers of periodontal pathologies, they do not fully explain their persistent ...
Michael Wolf +7 more
wiley +1 more source
Growth Factors and Their Roles in Multiple Sclerosis Risk
Frontiers in Immunology, 2021 BackgroundPrevious studies have suggested essential roles of growth factors on the risk of Multiple Sclerosis (MS), but it remains undefined whether the effects are causal.ObjectiveWe applied Mendelian randomization (MR) approaches to disentangle the ...
Hui Lu +6 more
doaj +1 more source